Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer

J Transl Med. 2024 Aug 21;22(1):778. doi: 10.1186/s12967-024-05583-z.

Abstract

The advent of polyadenosine diphosphate ribose polymerase inhibitors (PARPi) has brought about significant changes in the field of ovarian cancer treatment. However, in 2022, Rucaparib, Olaparib, and Niraparib, had their marketing approval revoked for third-line and subsequent therapies due to an increased potential for adverse events. Consequently, the exploration of new treatment modalities remains imperative. Recently, the integration of PARPi with immune checkpoint inhibitors (ICIs) has emerged as a potential remedy option within the context of ovarian cancer. This article offers a comprehensive examination of the mechanisms and applications of PARPi and ICIs in the treatment of ovarian cancer. It synthesizes the existing evidence supporting their combined use and discusses key considerations that merit attention in ongoing development efforts.

Keywords: Immune checkpoint inhibitor; Immunotherapy; Ovarian cancer; PARP inhibitors.

Publication types

  • Review

MeSH terms

  • Female
  • Humans
  • Immune Checkpoint Inhibitors* / pharmacology
  • Immune Checkpoint Inhibitors* / therapeutic use
  • Ovarian Neoplasms* / drug therapy
  • Poly(ADP-ribose) Polymerase Inhibitors* / pharmacology
  • Poly(ADP-ribose) Polymerase Inhibitors* / therapeutic use

Substances

  • Poly(ADP-ribose) Polymerase Inhibitors
  • Immune Checkpoint Inhibitors